Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Vascular Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Endoglin drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Endoglin (CD105) ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View Endoglin Products |
| Gene Delivery | Endoglin Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional screening. |
View Endoglin Products |
| Benchmark Ab | Anti-Endoglin Recombinant Antibody (Sequence of Carotuximab) Recombinant positive control for binding and functional benchmarks. |
View Endoglin Products |
| Validator | Endoglin siRNA Set Target-specific knockdown pool for target validation and specificity assays. |
View Endoglin Products |
| Related Target A | BMP9 (Bone Morphogenetic Protein 9) Primary ligand for Endoglin; essential for ligand-blocking and signaling assays. |
View BMP9 Products |
| Related Target B | VEGFA (Vascular Endothelial Growth Factor A) Synergistic angiogenic target; key for combination therapy and bispecific designs. |
View VEGFA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity |
| Ligand-blocking verification | Highly functional recombinant BMP9/BMP10 partner proteins available |
| Lack of Controls | Clinical Benchmark Antibodies (Carotuximab biosimilar) included |
| False Positives in knockdown | Sequence-verified siRNA pool included for specificity validation |
Live Endoglin R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Endoglin therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies (mAbs) to antibody-drug conjugates (ADCs) and bispecific constructs. Initially targeted as a monotherapy for anti-angiogenesis, clinical setbacks with first-generation mAbs have redirected the industry. The next wave of R&D is targeting Endoglin-positive tumor vasculature via cytotoxic payloads (ADCs) or dual-pathway inhibition (e.g., VEGF/Endoglin bispecifics) to bypass vascular endothelial resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Inhibrx, Tracon Pharmaceuticals | Advanced Solid Tumors, Sarcomas | Internalization Assay (Need high-purity ECD-Fc for conjugation & uptake assays) |
| Bispecific Antibodies | Roche, local biotech innovators | Ocular Diseases (wet AMD), Neovascular Cancers | Simultaneous Binding Validation (Need cross-species and tag-specific proteins) |
| Radioimmunotherapy | Abzena, Carmot Therapeutics | Metastatic Prostate Cancer, Renal Cell Carcinoma | Epitope Mapping & High-Affinity Screening (Need sequence-verified antigens) |